James M Frates insider trades

Open-market stock purchases and sales by James M Frates, Chief Financial Officer at Amylyx Pharmaceuticals, Inc, from SEC Form 4 filings since May 17, 2010.

Track record: 0% of 2 scored buys are up 5% or more since purchase, averaging -68%.

Recent trades

DateStockTradeValue
Sep 10, 2026AMLX Amylyx Pharmaceuticals, IncSold$315K
Sep 10, 2026AMLX Amylyx Pharmaceuticals, IncSold$34.6K
Aug 18, 2026AMLX Amylyx Pharmaceuticals, IncBought (not open market)—
Mar 5, 2026AMLX Amylyx Pharmaceuticals, IncBought (not open market)—
Mar 5, 2026AMLX Amylyx Pharmaceuticals, IncBought (not open market)—
Mar 2, 2026AMLX Amylyx Pharmaceuticals, IncSold$115K
Feb 2, 2026AMLX Amylyx Pharmaceuticals, IncSold$52.1K
Jan 6, 2026AMLX Amylyx Pharmaceuticals, IncSold$37K

Companies traded

  • AMLX Amylyx Pharmaceuticals, Inc: 1 buy, 17 sales, last Sep 10, 2026
  • SAGE Sage Therapeutics, Inc: 2 buys, 3 sales, last Jul 31, 2025
  • ALKS Alkermes plc.: 95 sales, last May 14, 2020

Get free alerts when James M Frates files a new trade →